Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
3.45 ^USD	-1.15%		-0.86%	-46.43%

Jul. 03	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT
Jul. 02	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT

Autolus Therapeutics plc Announces Resignation of Lucinda Crabtree as Chief Financial Officer

March 14, 2023 at 07:02 am EDT

Autolus Therapeutics plc announced that Dr. Lucinda Crabtree has provided notice of her resignation as Chief Financial Officer of the Company to pursue a new opportunity. Dr Crabtree will remain with the Company until Q3, 2023 in order to ensure a smooth and orderly transition. Autolus has initiated a formal search process for the selection of a new Chief Financial Officer.

Latest news about Autolus Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 03	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Jul. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	Jun. 28	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	Jun. 21	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	Jun. 18	MT
Autolus Therapeutics plc to Present Three Clinical Data Updates on Obecabtagene Autoleucel (obe-cel) in Relapsed/Refractory B-Cell Acute L-Cell Acute Lymphoblastic Leukemia Patients at the 2024 European Hematology Association Congress	Jun. 14	CI
Transcript : Autolus Therapeutics plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:40 PM	Jun. 12
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	Jun. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	Jun. 11	MT
Transcript : Autolus Therapeutics plc - Special Call	Jun. 01
Autolus Therapeutics plc Presents Long-Term Follow-Up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obecabtagene Autoleucel in an Oral Presentation at ASCO	May. 31	CI
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	May. 23	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	May. 21	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	May. 17	MT
Syncona notes Autolus's first quarter loss widens amid higher costs	May. 17	AN
Sector Update: Health Care Stocks Steady Pre-Bell Friday	May. 17	MT
Exchange-Traded Funds, Equity Futures Tread Water Pre-Bell Friday Amid Waning September Rate Cut Hopes	May. 17	MT
Transcript : Autolus Therapeutics plc, Q1 2024 Earnings Call, May 17, 2024	May. 17
Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises	May. 17	MT
Autolus Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 17	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	May. 16	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	May. 15	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	May. 14	MT
Autolus Therapeutics plc Appoint Michael Weston Bonney as Director	May. 13	CI
Autolus Therapeutics plc Appoints Ravi Madduri Rao as Director	May. 13	CI

Chart Autolus Therapeutics plc

Duration

Period

More charts

Company Profile

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Autolus Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.45 USD

Average target price

10.54 USD

Spread / Average Target

+205.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AUTOLUS THERAPEUTICS PLC	-46.43%	918M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs